Buy Mounjaro Online, where to buy Mounjaro Online, Where to buy Mounjaro in Canada, Buy Mounjaro in Australia, Buy Mounjaro online USA, Buy Mounjaro in UK
What is Mounjaro?
Mounjaro (tirzepatide) injection is used for type 2 diabetes in adults to lower blood sugar levels (blood glucose) and A1C levels. Mounjaro is a once-weekly injection that should be used with diet and exercise. Clinical trials for a 15 mg dose of Mounjaro (tirzepatide) for weight loss showed patients lost a mean of 20.9% of their body weight compared to 3.1% for placebo over 72 weeks. Mounjaro is FDA-approved for type 2 diabetes and Zepbound is FDA-approved to help with weight loss.
Mounjaro is the first GIP and GLP-1 receptor agonist, which works on the glucose-dependent insulinotropic polypeptide (GIP) receptors and the glucagon-like peptide-1 (GLP-1) receptors.
It works to lower blood sugar by helping the pancreas make more insulin, lowering the amount of sugar your liver makes, and slowing the rate food passes through your body, making you feel full longer. It does this by activating the two receptors, GIP and GLP-1, which are natural incretin hormones that help regulate blood sugar levels.
Mounjaro injection became an FDA-approved medicine on May 13, 2022, to improve blood sugar (glucose) levels in adults with type 2 diabetes mellitus when used together with diet and exercise. Mounjaro is not for use in people with type 1 diabetes. It is not known if this medicine can be used in people who have had pancreatitis.
Has the FDA approved Mounjaro for weight loss?
Yes, Mounjaro’s active ingredient tirzepatide is approved for weight loss by Eli Lilly and Company.
Mounjaro is an FDA-approved medicine used to improve blood sugar (glucose) levels in adults with type 2 diabetes mellitus when used together with diet and exercise.
Furthermore, Mounjaro’s active ingredient tirzepatide was used in the Phase 3 SURMOUNT-1 72-week weight loss clinical trials. The mean tirzepatide weight loss was 15% for the 5mg dose, 19.5% for the 10mg dose, 20.9% for the 15mg dose, and 3.1% for placebo. Lastly, The trial included patients who were overweight, obese, and had a weight-related health issue but excluded patients with diabetes.
